Kathleen Moore, MD, MS - Targeting Disease Progression in Advanced Ovarian Cancer: Can Combination PARP Inhibitors and Immune Checkpoint Inhibitors Improve Outcomes?

Please visit answersincme.com/AXF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gynecologic cancers discusses the potential role of combination poly (ADP-ribose) polymerase (PARP) inhibitors and immune checkpoint inhibitors (ICIs) in improving outcomes in advanced ovarian cancer.Upon completion of this activity, participants should be better able to: Discuss the clinical rationale for combining PARP inhibitors with ICIs; Review the clinical profile of PARP inhibitors in combination with ICIs for patients with advanced ovarian cancer; and Identify the potential place in therapy for PARP inhibitors in combination with ICIs in advanced ovarian cancer.

There are no comments yet.

Please log in to write the first comment.